Audentes Therapeutics Garners $42,500,000 Series B Financing Round

  • Feed Type
  • Date
    12/3/2014
  • Company Name
    Audentes Therapeutics
  • Mailing Address
    101 Montgomery Street. San Francisco, CA 94104 USA
  • Company Description
    Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology.
  • Website
    http://www.audentestx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $42,500,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The additional funding will allow Audentes to achieve key clinical development milestones for its two lead programs and to continue research and in-licensing efforts to become a worldwide leader in gene therapy.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy